Pro-gastrin-releasing peptide - A useful tumour marker in small-cell lung carcinomas;Pro-gastrin-releasing peptide (ProGRP) - Ein tumormarker für das kleinzellige bronchialkarzinom

Atemwegs- und Lungenkrankheiten

Volumn 30, Issue 8, 2004, Pages 367-370

  Oremek, G M ^a,c   Oertl, A ^a   Sauer Eppel, H ^a   Siekmeier, R ^a,b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Bundesinst Arzneimit Medizinprod   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Benign pulmonary diseases; Bronchial carcinoma; Pro gastrin releasing peptide (ProGRP); Tumour marker

Indexed keywords

GASTRIN RELEASING PEPTIDE; PROGASTRIN; PROGASTRIN RELEASING PEPTIDE; PROTEIN PRECURSOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CHRONIC BRONCHITIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; LUNG CARCINOMA; LUNG DISEASE; LUNG FIBROSIS; LUNG SARCOIDOSIS; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE;

EID: 4444247731     PISSN: 03413055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Stieber P., A.-C. Arousson, P. Bialk, J. Kulpa, R. Lamerz, R. Molina, A. and van Daalen: Tumour markers in lung cancer. Anticancer Res. 19, 2785-2820(1999).
2. Oremek G.M., U.B. Seiffert: Cyfra 21-1 - ein ge-eigneter Tumormarker in der Diagnostik nichtkleinzelliger Bronchialkarzinome. Med. Welt 47, 335-338(1996).
3. Oremek G.M., U.B. Seiffert, R. Wagner: TU-M2-PK: ein neuer Tumormarker in der pneumologischen Diagnostik. Atemw.-Lungenkrh. 21, 340-342(1995).
4. Pujol J.L., J.M. Boher, J. Grenier, X. Quantin: Cyfra 21-1, neuron-specific enolase and prognosis of nonsmall cell lung cancer: prospective study in 621 patients. Lung Cancer 31, 221-231 (2001).
5. Stieber P., H. Dienemann, U.M. Schmitt, J. Reinmiedl, U. Hasholzner, W. Reiter, K. Hofmann, A. Schalhorn, K. Yamaguchi: Pro-gastrin-releasing peptide (ProGRP) - a new marker in small-cell lung carcinomas. J. Lab. Med. 21, 336-344 (1997).
6. Yamaguchi K., P. Stieber: Diagnosis of small cell lung cancer by pro-gastrin-releasing peptide (ProGRP). J. Lab. Med. 27, 26-30 (2003).
7. Stieber P., H. Dienemann, A. Schalhorn, U.M. Schmitt, J. Reinmiedl, K. Hofmann, K. Yamaguchi: Pro-gastrin-releasing peptide (ProGRP) - a useful marker in small-cell lung carcinomas. Anticancer Res. 19, 2673-2678 (1999).
8. Inaji H., Y. Komoike, K. Motomura, M. Higashiyama, M. Ohtsuru, H. Funai, T. Kasugai, H. Koyama: Demonstration and diagnostic significance of pro-gastrin-releasing peptide in medullary thyroid carcinoma. Oncology 59, 122-125 (2000).
9. Shibayama T., H. Ueoka, K. Nishii, K. Kiura, M. Tabata, K. Miyatake, T. Kitajima, M. Harada: Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer 32, 61-69 (2001).
10. Lamy P., J. Grenier, A. Kramar, J.L. Pujol: Progastrin-releasing peptide, neuron-specific enolase and chromogranin A as serum markers of small cell lung cancer. Lung Cancer 29, 197-203 (2000).
11. Schneider J., M. Philipp, L. Salewski, H.G. Velcovsky: Pro-gastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) in therapy control of patients with small-cell lung cancer. Clin. Lab. 49, 35-42 (2003).
12. Schneider J., M. Philipp, H.G. Velcovsky, H. Morr, N. Katz: Pro-gastrin-releasing peptide (ProGRP), neuron-specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Anticancer Res. 23, 885-894 (2003).
13. Niho S., Y. Nishiwaki, K. Goto, H. Ohmatsu, T. Matsumoto, F. Hojo, Y. Ohe, T. Kakinuma, R. Kodama: Significance of serum pro-gastrin-releasing as a predictor of relapse of small-cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer 27, 159-167 (2000).
14. Sunaga N., S. Tsuchiya, K. Minato, S. Watanabe, N. Fueki, H. Hoschino, T. Makimoto, S. Ishihara, R. Saito, M. Mori: Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer. Oncology 57, 143-148 (1999).
15. Schmidt L., C. Uhde, R.M. Huber: Nachsorge bei malignen Tumoren. In: Schalhorn A.: Manual Tumoren der Lunge und des Mediastinums. Zuckschwerdt, München 2000, 105-113.